From Good Intentions to Violation — A Pressure Map and Four Psychological Drivers

"I want to get good medicine to patients" — that intention is real. And yet, across the seven annual reports from fiscal 2019 through 2025, healthcare institution monitors captured a cumulative total of approximately 186 suspected violations (an editorial sum across seven report editions). Most of the people at the center of those cases were not bad actors. They were ordinary representatives. Sales targets, launch deadlines, KOL relationships, competitive pressure — pressure has a map. Inside representatives under that pressure, four psychological drivers chain together and bend good intentions, increment by increment. This series traces that chain through real incidents.

So What / So Why — The Core Argument

Reading the approximately 186 violations documented across seven annual reports under the Guidelines for Promotional Activities of Prescription Drugs (effective 2018), you find almost no cases where a representative planned to deceive anyone. The vast majority acted under the belief that "showing this data will help the doctor make a better decision," or "I was only honestly explaining our differentiator," or "I didn't mention it because no one asked." Violations do not arise from intent — they arise from the distortion of intent.

Why does this matter? Because physicians use information from pharmaceutical companies as material for prescribing decisions. If only efficacy data reaches the physician and safety risks are not conveyed, the physician prescribes without knowing those risks. If data is selectively presented, the physician builds a judgment on a faulty foundation. Individual cases may not produce visible harm, but systematic distortion of information leads to population-level harm in clinical care.

This series, "Inside the Maker," is not a search for villains. By understanding the structure that generated those approximately 186 cumulative cases — the pressure map and the four psychological drivers — it provides material for asking whether your own judgment has entered the same chain. This first installment serves as an introduction, laying out the map for the series as a whole.

The Structure of Pressure — Who, By When, With What Numbers

The source of pressure on a representative is not only the direct manager. Pressure exists on multiple levels, and each layer affects judgment at different moments and in different forms.

Sales and Share Targets, Quarterly Quotas

MRs are often assigned individual targets for adopted institutions, prescription volume, and revenue. When chasing numbers toward a quarter's end, the calculation "if I show this data, they'll adopt the product" accelerates. The reverse fear — that laying out safety information carefully might make the physician hesitate — makes omitting safety information feel rational.

Launch and Indication Expansion Deadlines

Immediately after a new drug is approved, expectations of blockbuster status collide with the 14-day prescribing restriction. Under internal pressure to maximize adopted hospital count within the first year of launch, violations that "implicitly encourage use inconsistent with the prescribing day limit" appeared in multiple cases in the fiscal 2019 annual report. During indication expansion, the motive to "raise physician expectations before approval" triggers hints about off-label use.

KOL Relationship Maintenance

Company-sponsored medical lectures carry a long-term relationship with the speaker as backdrop. When a speaker promotes the company's product too aggressively, the sponsoring company tends not to intervene — treating lecture content as "the speaker's own judgment." The Guidelines specify that sponsoring companies are responsible for reviewing the content of lecture materials, but the fiscal 2020 and fiscal 2022 annual reports document cases where this review was not carried out.

Competitive Response and Internal Politics

In markets where biosimilars or generics have entered, the pressure to defend share spikes. The increase in disparagement of competitor companies to a combined eight cases across the fiscal 2024 and 2025 annual reports (four cases in the fiscal 2024 edition, four in the fiscal 2025 edition) may reflect this intensifying competition. Internally, the fact that a manager approved a slide functions as official sanction, removing the representative's motivation to question whether the content is appropriate.

Caught Between Incentive Design and Regulation

When evaluation systems are tied to adopted prescription count or sales achievement rate, increasing the precision of efficacy claims aligns with incentives — while no mechanism exists to evaluate the accuracy of safety information delivery. The Guidelines mandate balance between efficacy and safety, but if incentives measure only one side, behavior naturally tilts. This gap between what regulation requires and what incentives reward is the structural breeding ground for violations.

Internal Reconstruction — Belief, Feeling, and Psychological Driver

Pressure comes from outside. But it becomes a violation only when something happens inside the representative. For each of the four drivers below, the sequence is: belief (what the person held to be correct) → feeling (the emotion in the moment) → psychological mechanism (what was operating beneath the surface). This is not the story of any specific individual — it is an extraction of psychological patterns observable across the approximately 186 cumulative cases.

① Motivated Reasoning

Belief: "This drug genuinely works for patients. Therefore showing this data is the right thing to do."
Feeling: Conviction and a sense of mission. A sincere desire for the physician to know.
Psychological mechanism: The conclusion comes first (this drug is good), and only supporting data is selected. Contradictory data is reinterpreted as "an unusual patient population" or "an atypical trial" and excluded from awareness. This is the textbook form of what psychologist Ziva Kunda (1990) formalized as motivated reasoning — it is not malice but conviction that distorts information. Because the representative genuinely feels they are being honest, they do not notice until someone points it out from outside.

② Local Justification

Belief: "This one slide is fine. The surrounding context compensates."
Feeling: Attention to individual parts, numbness to the whole. Comfort in "this piece is accurate, so it's okay."
Psychological mechanism: By evaluating each decision only at the level of "this step," the person loses sight of the distorted impression the full presentation gives the physician. The pattern of first saying "this is off-label, but speaking in general terms" before stepping into problematic territory is the textbook example. Each step looks legitimate, but the chain completes a violation. This is close to what Bazerman and Tenbrunsel (2011) call "ethical fading" — awareness that a substantial moral decision is being made quietly dissolves.

③ Omission Bias

Belief: "I didn't say it — I didn't lie. The doctor can ask if they want to know."
Feeling: Self-absolution from not having committed an active deception. A lightening of guilt.
Psychological mechanism: An intuition operates that actively fabricating information and simply staying silent are morally distinct (commission bias). The justification "I didn't mention it because no one asked" recurs across safety minimization cases documented across report years. But the Guidelines mandate proactive provision of both efficacy and safety information — omission is a violation on equal footing with fabrication. The intuition that "omission is not a lie" renders transparent what is, by regulatory definition, equivalent to lying.

④ Diffusion of Responsibility

Belief: "The physician is the one who prescribes. I am only providing information."
Feeling: Psychological distance between one's own act and its consequences for the patient. A sense of security.
Psychological mechanism: Statements like "my manager approved this slide," "other companies do the same," and "the physician decides" distribute responsibility for one's own judgment across others. As social psychology has repeatedly shown, the more diffuse the responsibility, the weaker individual inhibition becomes. The cases of sponsoring companies that failed to review speaker content after the fact show a double diffusion of responsibility — "the speaker said it."

These four drivers do not work independently — they chain. "For the patient (driver ①) → present only this data (local justification ②) → no need to mention side effects (omission ③) → the doctor decides (externalization ④)." A single violation is completed through this chain. Noticing where in the chain you are is the only practical lever that stops a violation from forming.

The Underlying Incidents — Confirming the Chain in Three Cases

All three cases below are documented in the Ministry of Health, Labour and Welfare's annual monitoring reports for their respective fiscal years. What comes through is that the representatives were not "unusually bad actors" — they were ordinary makers.

Case 1: The Day a Personal Impression Became Data (March 2019 Report — No Evidence)

Case 2: The Gap Five Words Created (March 2019 Report — Off-Label Implication)

Case 3: "We Don't Show the Domestic Data" Was Shared Across the Organization (March 2022 Report — Safety Minimization)